证券之星消息，12月10日动物保健板块较上一交易日下跌0.31%，*ST绿康领跌。当日上证指数报收于 3900.5，下跌0.23%。深证成指报收于13316.42，上涨0.29%。动物保健板块个股涨跌见下表： 从资金流向上来看，当日动物保健板块主力资金净流出1398.26万元，游资资金净流出1834.36万元，散 户资金净流入3232.62万元。动物保健板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600201 | 生物股份 | 14.53 | 1.18% | 39.53万 | | 5.60亿 | | 300119 | 瑞普生物 | 19.24 | 0.79% | 2.69万 | 5155.97万 | | | 002141 | 贤丰控股 | 3.82 | 0.53% | 17.77万 | 6770.24万 | | | 920275 ...

证券之星消息，12月8日动物保健板块较上一交易日上涨1.81%，生物股份领涨。当日上证指数报收于 3924.08，上涨0.54%。深证成指报收于13329.99，上涨1.39%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600201 | 生物股份 | 14.39 | 7.39% | 71.75万 | | 10.14亿 | | 600195 | 中牧股份 | 8.09 | 1.25% | 18.04万 | | 1.46亿 | | 920970 | 大禹生物 | 7.88 | 0.90% | ● 1.01万 | | 802.74万 | | 920729 | 永顺生物 | 8.85 | 0.80% | 6781.98 | | 602.31万 | | 300119 | 瑞普生物 | 19.37 | 0.73% | 3.19万 | | 6169.99万 | | 002688 | 金河生物 | 6.16 | 0.65% | 13.17万 | | 8088. ...

Core Viewpoint - The animal health sector experienced a decline of 0.7% on December 2, with Shenyuan Biological leading the drop. The Shanghai Composite Index closed at 3897.71, down 0.42%, while the Shenzhen Component Index closed at 13056.7, down 0.68% [1][2]. Stock Performance Summary - The closing prices and performance of key stocks in the animal health sector are as follows: - Shenyuan Biological (688088) closed at 9.28, down 2.93% with a trading volume of 40,900 shares and a turnover of 38.24 million yuan [2]. - Shengong Holdings (002141) closed at 4.13, down 0.96% with a trading volume of 387,200 shares and a turnover of 159 million yuan [1]. - Other notable stocks include: - Biological Shares (600201) at 12.45, up 1.63% [1]. - Zhongmu Shares (600195) at 7.64, down 0.26% [1]. - Jinhai Biological (002688) at 6.17, down 0.32% [1]. Capital Flow Analysis - The animal health sector saw a net outflow of 10.78 million yuan from institutional investors, while retail investors had a net inflow of 16.68 million yuan [2][3]. - Key capital flow details include: - Shengong Holdings had a net inflow of 8.69 million yuan from institutional investors [3]. - ST Green Kang (002868) experienced a net inflow of 5.73 million yuan from institutional investors [3]. - Other stocks like Hailey Biological (603718) and Jinhai Biological (002688) showed mixed capital flows with varying net inflows and outflows [3].

Core Viewpoint - The animal health sector experienced a decline of 0.48% on December 1, with *ST Lvkang leading the drop, while the overall market indices showed positive performance with the Shanghai Composite Index rising by 0.65% and the Shenzhen Component Index increasing by 1.25% [1][2]. Market Performance - The closing price of *ST Lvkang was 39.35, reflecting a decrease of 3.41% with a trading volume of 30,400 shares and a transaction value of 122 million yuan [2]. - Other notable stocks in the animal health sector included: - Dayu Biological: Closing price 8.26, up 2.10% [1] - Haili Biological: Closing price 6.86, up 1.03% [1] - Qihua Biological: Closing price 15.85, up 0.51% [1] - Repu Biological: Closing price 19.83, down 0.10% [1][2]. Capital Flow - The animal health sector saw a net outflow of 29.57 million yuan from institutional investors, while retail investors contributed a net inflow of 3.27 million yuan [2][3]. - Specific stock capital flows included: - Jinhai Biological: Net inflow from institutional investors of 3.13 million yuan [3]. - Haili Biological: Net inflow from institutional investors of 2.06 million yuan [3]. - Repu Biological: Net inflow from retail investors of 2.81 million yuan [3].

证券代码：688098 证券简称：申联生物 公告编号：2025-040 一、本次解除冻结的股份原冻结情况 股东 UBI 所持公司 1,815,221 股股份存在被司法冻结的情形，内容详见公司 于 2019 年 12 月 5 日在上海证券交易所网站（www.sse.com.cn）披露的《申联生 物医药(上海)股份有限公司关于持股 5%以上股东股份被司法冻结的公告》（公 告编号：2019-008）。 股东 UBI 被法院强制执行被动减持公司股份 730,000 股，内容详见公司于 2023 年 3 月 23 日在上海证券交易所网站（www.sse.com.cn）披露的《申联生物 医药(上海)股份有限公司持股 5%以上股东部分股份被动减持的公告》（公告编 号：2023-004）。2023 年 3 月 30 日，股东 UBI 被法院强制执行被动减持公司股 份 4,000 股作为前述事项执行费，因此 UBI 持有的公司股份冻结数量为 1,081,221 股。 申联生物医药(上海)股份有限公司 关于持股 5%以上股东所持股份解除冻结的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏， ...

申联生物医药（上海）股份有限公司 简式权益变动报告书 证券代码：688098 证券简称：申联生物 申联生物医药（上海）股份有限公司 简式权益变动报告书 上市公司：申联生物医药（上海）股份有限公司 股票上市地：上海证券交易所 股票简称：申联生物 股票代码：688098 信息披露义务人：UNITED BIOMEDICAL,INC. 住所：25 Davids Drive Hauppauge, NY 11788, USA 通讯地址：25 Davids Drive Hauppauge, NY 11788, USA 股份变动性质：股份减少 签署日期：2025 年 11 月 28 日 申联生物医药（上海）股份有限公司 简式权益变动报告书 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司收购管理办法》（以下简称"《收购办法》"）、《公开发行证券的公 司信息披露内容与格式准则第 15 号—权益变动报告书》（以下简称"《准则 15 号》"）及相关的法律、法规编写本报告书。 二、信息披露义务人签署本报告已获得必要的授权和批准，其履行亦不违反 信息披露义务人章程或内部规则中的 ...

证券代码：688098 证券简称：申联生物 公告编号：2025-041 申联生物医药（上海）股份有限公司 关于持股 5%以上股东权益变动触及 5%整数倍的 提示性公告 信息披露义务人美国联合生物医药公司保证向本公司提供的信息真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏，并对其真实性、准确性和完整性依法承担 法律责任。本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 一、 信息披露义务人及其一致行动人的基本信息 2.信息披露义务人信息 | 信息披露义务人名称 | 投资者身份 | 统一社会信用代码 | | --- | --- | --- | | □ | 控股股东/实控人 | | | 美国联合生物医药公 □ | 控股股东/实控人的一致 | □ _____________ | | 司 | 行动人 | 不适用 ☑ | | | ☑ 其他直接持股股东 | | 二、 权益变动触及 5%整数倍的基本情况 公司于近日收到美国联合生物医药公司（UNITED BIOMEDICAL, INC.以下 简称"UBI"）出具的《UBI 关于权益变动触及 5%整数倍的告知函》，本次权益 变动后信息披露义务人合计持有 ...

Core Viewpoint - The company received a notification from United BioPharma regarding a planned share reduction through centralized bidding from November 24 to 28, 2025, which will decrease the shareholder's stake from 10.52% to 10.00% [1] Summary by Relevant Sections - **Shareholder Action** - The shareholder will reduce their holdings by selling shares, resulting in a total of 41,064,498 shares held post-reduction [1] - **Impact on Company** - The reduction does not violate any commitments, does not trigger mandatory tender offer obligations, and will not lead to changes in the company's controlling shareholder or actual controller [1] - The operational impact on the company is deemed minimal [1]

Core Viewpoint - UNITEDBIOMEDICAL, INC. has reduced its shareholding in the company by 2.1354 million shares, representing 0.52% of the total share capital, due to its own funding needs, without affecting the actual control of the company or harming the interests of the company and other shareholders [1] Summary by Relevant Sections - Shareholding Reduction - UNITEDBIOMEDICAL, INC. sold a total of 2.1354 million shares from November 24 to November 28, 2025 [1] - Post-reduction, UNITEDBIOMEDICAL, INC. holds 41.0645 million shares, which is 10.00% of the total share capital [1] - The previous shareholding percentage was 10.52% [1]

Group 1 - The company, Shenlian Bio, reported that as of September 30, 2025, the total number of common stock shareholders is 12,388 [1]